Please use this identifier to cite or link to this item:
|Title:||Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.|
Kwo, Paul Y.
Romero Gomez, Manuel
Zarski, Jean Pierre
Foster, Graham R.
Jacobson, Ira M.
Yang, Jenny C.
Pang, Philip S.
Symonds, William T.
McHutchison, John G.
Muir, Andrew J.
|Keywords:||Virus de l'hepatitis C|
Hepatitis C virus
|Publisher:||Massachusetts Medical Society|
|Abstract:||BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection. METHODS: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection. Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection. The rates of sustained virologic response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 weeks of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 weeks of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 weeks of ledipasvir-sofosbuvir plus ribavirin. No patient in either 12-week group discontinued ledipasvir-sofosbuvir owing to an adverse event. The most common adverse events were fatigue, headache, insomnia, and nausea. CONCLUSIONS: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection. (Funded by Gilead Sciences; ION-1 ClinicalTrials.gov number NCT01701401.).|
|Note:||Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa1402454|
|It is part of:||New England Journal of Medicine, 2014, vol. 370, num. 20, p. 1889-1898|
|Appears in Collections:||Articles publicats en revistes (Medicina)|
Files in This Item:
|661902.pdf||383.08 kB||Adobe PDF||View/Open|
|nejmoa1402454_appendix.pdf||607.76 kB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.